(d) Included in Other expense/(income), net
(e) Included in Special and acquisition-related charges
(f) Included in Equity income
SCHERING-PLOUGH CORPORATION
Report for the period ended September 30 (unaudited):
GAAP Net Sales by Key Product
(Dollars in millions) Third Quarter Nine Months
--------------------- -------------------
2008 2007 % 2008 2007 %
---- ---- - ---- ---- -
HUMAN PRESCRIPTION
PHARMACEUTICALS a/ $3,539 $2,291 54% $10,798 $7,209 50%
REMICADE 564 426 32% 1,627 1,193 36%
TEMODAR 273 215 27% 760 627 21%
NASONEX 258 242 6% 876 821 7%
PEGINTRON 235 221 6% 689 672 3%
CLARINEX / AERIUS 176 171 3% 630 625 1%
FOLLISTIM/PUREGON c/ 142 - - 450 - -
NUVARING c/ 118 - - 330 - -
CLARITIN RX 87 83 5% 326 297 10%
INTEGRILIN 84 78 7% 236 241 (2%)
CAELYX 80 64 24% 232 191 22%
ZEMURON c/ 72 - - 202 - -
AVELOX 65 78 (17%) 274 269 2%
REBETOL 63 60 5% 193 206 (6%)
SUBUTEX / SUBOXONE 63 55 15% 178 163 10%
REMERON c/ 61 - - 190 - -
INTRON A 61
'/>"/>
| SOURCE Schering-Plough Corporation Copyright©2008 PR Newswire. All rights reserved |